Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.
You may also be interested in...
Agennix Halves Headcount, Closes Houston Site, Following Talactoferrin Failure In NSCLC
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.
Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.